Japan COVID-19 cases hit 1 million as infections spread beyond Tokyo

New cases in Tokyo hit 4,515, the second highest after Thursday’s record 5,042, while the neighbouring, populous prefecture of Kanagawa saw its cases soaring to more than 2,000, quadrupling in less than two weeks.

Reuters

August 06, 2021 / 15:43 IST

Source: AP

Japan reached the milestone of one million coronavirus cases on Friday, domestic media reported, as infections soared in Olympic host Tokyo and other urban areas as the country struggled to contain the Delta variant.

New cases in Tokyo hit 4,515, the second highest after Thursday’s record 5,042, while the neighbouring, populous prefecture of Kanagawa saw its cases soaring to more than 2,000, quadrupling in less than two weeks.

Infections in Osaka, the biggest city in the country’s west, also rose to a record-breaking 1,310, in a sign the pathogen is quickly spreading outside Tokyo.

The total number of cases since the pandemic began last year is now above one million, tarnishing the country’s early success in containing the disease.

While the contagion appears to quickly spread from the capital to other regions, Prime Minister Yoshihide Suga struck a cautious tone on expanding a state of emergency to the entire country.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show